Eli Lilly and Co (LLY) Actualités

FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity

FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe...

Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease

Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt

Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt PR...

Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease

Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately...

Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer

Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in...

Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting

Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic...

Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase

Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase PR...

CORE Kidney, Boehringer Ingelheim and Lilly Are Turning Up the Volume on Kidney Health at the 2025 Tournament of Roses® Parade

CORE Kidney, Boehringer Ingelheim and Lilly Are Turning Up the Volume on Kidney Health at the 2025 Tournament...

Lilly announces $3 billion expansion of its recently acquired manufacturing facility in Wisconsin

Lilly announces $3 billion expansion of its recently acquired manufacturing facility in Wisconsin PR...

Form 3 - Initial statement of beneficial ownership of securities